4523 To News Today

Biogen’s new CEO, Christopher Viehbacher, said the company is well positioned to return to sustainable growth.

Biogen will record a one-time charge of about $60 million related to close-out costs of the program.

When Biogen reports earnings Wednesday, investors won’t be paying much attention to the numbers. Biogen is in a period of cost-cutting, and trying to build...

Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer’s drug.

By Colin Kellaher Merck & Co. and Eisai are ending a late-stage study of the cancer drugs Keytruda plus Lenvima in patients with certain types of...

Two similar Alzheimer’s drugs are likely to be on the market and accessible for Medicare patients sometime in 2024.

The FDA gives Biogen’s Alzheimer’s drug full approval, Janet Yellen criticizes China over chip measures on Beijing trip, and other news to start your day.

Federal approval for the treatment marks a major step forward in making the drug accessible. The Centers for Medicare and Medicaid Services said in January...

The agency that oversees the medical program for seniors will pick up the bill only if doctors submit treatment data to a nationwide registry.

Even after the latest Lilly data showing that its drug slowed the disease, the agency that runs the program isnt budging.